Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” ; volume:40 ; number:9 ; day:19 ; month:7 ; year:2022 ; pages:929-930 ; date:9.2022
PharmacoEconomics ; 40, Heft 9 (19.7.2022), 929-930, 9.2022
- Urheber
-
Gandjour, Afschin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-022-01170-6
- URN
-
urn:nbn:de:101:1-2022102602422914485800
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gandjour, Afschin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Heart failure
Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
Advance Care Planning (ACP) in Medicare Beneficiaries with Heart Failure
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
SGLT2 inhibitors in heart failure with reduced ejection fraction
Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Heart failure
Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
Advance Care Planning (ACP) in Medicare Beneficiaries with Heart Failure
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
SGLT2 inhibitors in heart failure with reduced ejection fraction
Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Heart failure
Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
Advance Care Planning (ACP) in Medicare Beneficiaries with Heart Failure
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review